

ASX ANNOUNCEMENT

Results of the Annual General Meeting Held on Thursday 13 November 2014

Sydney, Australia, 13 November 2014: In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

| For | Against | Abstain | Proxy's discretion |
|------------|-----------|---------|--------------------|
| 11,021,755 | 1,293,079 | 22,858 | 10,977,948 |

The motion was carried as an ordinary resolution on a show of hands.

Re-election of Director - Mr Peter Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

| For | Against | Abstain | Proxy's discretion |
|------------|---------|---------|--------------------|
| 11,904,405 | 643,101 | 53,206 | 10,977,948 |

The motion was carried as an ordinary resolution on a show of hands.

Approval of 10% Placement Capacity

The instructions given to validly appointed proxies in respect of the resolution were as follows:

| For | Against | Abstain | Proxy's discretion |
|------------|-----------|---------|--------------------|
| 10,592,030 | 1,845,898 | 162,784 | 10,977,948 |

The motion was carried as a special resolution on a show of hands.

For further information, please contact the persons outlined below, or visit the Benitec website at www.benitec.com.

| Company | Investor relations |
|---|---|
| Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com | Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au |

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT; OTC: BTEBY) which has developed a patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS and retinitis pigmentosa. For more information visit www.benitec.com